Shots:
- Incyte reported updated data from two P-I trials showing the safety, tolerability, and efficacy of INCA033989 (INCA33989-101 and INCA33989-102) in 455 adults(age≥18) with mutCALR-positive MPNs, including ET & MF, findings were presented at ASH’25
- In ET pts receiving higher starting doses of INCA033989 (400–2,500 mg; n=30), 90% achieved a HR, including 83.3% with CHR and 46.4% with durable (≥12 wks) CHR. At lower doses (24–250 mg; n=25), 88% achieved a HR, 68% achieved CHR, and 44% of those had durable CHR
- Molecular responses were common, rapid, and durable. A mutCALR VAF reduction occurred in 96.2% of evaluable ET pts, with 52% achieving ≥25% and 31% ≥50% reduction. Reductions typically appeared within 3–6 mos. and persisted, with greater and more consistent decreases at higher doses
Ref: Incyte | Image: Incyte | Press Release
Related News: Incyte’s Minjuvi Combination Gains the CHMP’s Positive Opinion for R/R Follicular Lymphoma (FL)
PharmaShots, your go-to media platform for customized news across multiple therapeutic areas. For more information, reach us at connect@pharmashots.com
